{"product_id":"genommalab-pestle-analysis","title":"Genomma Lab Internacional PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain strategic clarity with our PESTLE Analysis tailored for Genomma Lab Internacional—uncover how regulatory shifts, economic cycles, and consumer trends affect growth and risk. Perfect for investors, consultants, and executives, this concise briefing pinpoints actionable opportunities and threats. Buy the full version now for an editable, in-depth report you can use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical stability in Latin America\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeopolitical stability in Latin America affects Genomma Lab Internacional’s operations across Mexico, Brazil, Argentina and others, where sudden regulatory changes or trade barriers can disrupt supply chains; 2024 cross-border trade volatility raised logistics costs by an estimated 8–12% in the region. \u003c\/p\u003e\n\u003cp\u003eIn 2025 monitoring Mexico’s diplomatic ties with key partners—US trade flows (over 80% of Mexico’s exports transit US routes) and 2024 tariff alerts—remains essential to protect timely shipments and margins. \u003c\/p\u003e\n\u003cp\u003eAnalysts should quantify risks from regional leadership transitions: between 2020–2024, policy shifts in Brazil and Argentina altered tax\/incentive regimes, changing manufacturing investment returns by roughly 2–4 percentage points, impacting site selection and capex decisions for pharmaceutical production. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare spending policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic health initiatives and government-funded programs in Latin America and the US increasingly favor self-care, with WHO estimating a 15–20% shift to OTC treatments in primary care by 2024; this boosts demand for Genomma Lab’s affordable OTC portfolio.\u003c\/p\u003e\n\u003cp\u003eGovernments aiming to cut public healthcare spending—Latin America public health expenditure rose to about 7.8% of GDP in 2023—are promoting non-prescription solutions, creating policy tailwinds. \u003c\/p\u003e\n\u003cp\u003eGenomma Lab must align product registration, pricing and marketing with national health agendas to capture share; OTC sales growth in the region averaged ~6–8% CAGR in 2022–2024, underscoring the opportunity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade agreements and tariff structures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChanges in trade pacts like USMCA and Mercosur shift import\/export costs for Genomma Lab, where raw-material imports accounted for ~28% of COGS in 2024; tariff adjustments of 5–15% could widen gross margins by 1–3 ppt or compress them similarly. Political moves on import duties in Mexico, US, Brazil and Argentina materially affect pricing strategies across key markets generating ~60% of 2024 revenues. Maintaining an agile supply chain, including nearshoring and diversified sourcing, is essential to hedge against protectionist risks and preserve a target EBITDA margin near 18–20%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory oversight on advertising\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical pressure for tighter regulation of health-product marketing has led to stricter guidelines on communicating pharmaceutical benefits; in Mexico, COFEPRIS enforcement actions rose ~18% in 2024, increasing compliance costs for firms like Genomma Lab.\u003c\/p\u003e\n\u003cp\u003eLegislatures and consumer-protection agencies are scrutinizing claims to curb misleading wellness advertising, with fines averaging MXN 1.2–3.5 million in recent high-profile cases, raising legal risk for aggressive marketers.\u003c\/p\u003e\n\u003cp\u003eGenomma must navigate evolving political landscapes to preserve its direct-response, high-ROI marketing model while potentially reallocating up to 2–4% of revenue toward compliance and legal contingencies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCOFEPRIS enforcement +18% (2024)\u003c\/li\u003e\n\u003cli\u003eAverage fines MXN 1.2–3.5M\u003c\/li\u003e\n\u003cli\u003eEstimated 2–4% revenue shift to compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTaxation and fiscal reforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpfiscal policies in emerging markets can push corporate tax rates higher or introduce vat consumption levies on personal care fiscal measures raised certain federal and mexico discussions targeted excise-like charges for non-essential goods risking margin compression genomma lab internacional.\u003e\n\u003cppolitical drives for redistribution or infrastructure funding often seek revenue from large corporates in latin american tax targets rose by of gdp several countries increasing audit and compliance risks.\u003e\n\u003cp\u003eTracking fiscal trajectories per country is essential for long-term forecasting, given Genomma Lab's 2024 Ebitda margin of ~18–20% and dividend policy sensitivity to tax shocks and repatriation rules.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEmerging-market VAT\/excise risk: potential margin hit\u003c\/li\u003e\n\u003cli\u003eHigher corporate tax\/withholding increases cash-tax burden\u003c\/li\u003e\n\u003cli\u003e2024 regional tax targets up ~1.5–2% of GDP, raising audit pressure\u003c\/li\u003e\n\u003cli\u003eEssential to model country-level fiscal scenarios for dividends\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppolitical\u003e\u003c\/pfiscal\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLatin America political risk squeezes pharma margins: fines, tariffs \u0026amp; 2–4% compliance hit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical volatility in Latin America impacts supply chains, tariffs and compliance: 2024 COFEPRIS actions +18%, avg fines MXN 1.2–3.5M, raw-materials = 28% COGS, tariffs ±5–15% (±1–3 ppt gross margin), OTC CAGR 2022–24 ~6–8%; model 2–4% revenue reallocation to compliance and target EBITDA 18–20% at risk from fiscal\/tax shifts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOFEPRIS actions\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg fines\u003c\/td\u003e\n\u003ctd\u003eMXN 1.2–3.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials (% COGS)\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff swing\u003c\/td\u003e\n\u003ctd\u003e±5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC CAGR\u003c\/td\u003e\n\u003ctd\u003e6–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance hit\u003c\/td\u003e\n\u003ctd\u003e2–4% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Genomma Lab Internacional across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section backed by current data and trends to identify threats and opportunities for executives, consultants, and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Genomma Lab Internacional's PESTLE into a clean, shareable summary—visually segmented by category and written in plain language—to speed decision-making in meetings, slide decks, or cross‑team planning while allowing easy note additions for region- or product-specific context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a multinational operating across Latin America, Genomma Lab faces FX exposure versus MXN and USD; 2024 saw MXN volatility at ±7.5% y\/y and several regional currencies depreciating 10–25%, which can compress consolidated EBITDA margins (reported 2023 adjusted EBITDA margin 18.2%).\u003c\/p\u003e\n\u003cp\u003eDevaluations raise costs for dollar-denominated debt and imported APIs—Genomma reported net debt of ~$240m in FY2023—heightening interest and input-cost pressure.\u003c\/p\u003e\n\u003cp\u003eFinancial teams must monitor and deploy hedges: in 2024 similar consumer-health peers used FX forwards and natural hedges covering 50–80% of short-term exposure to stabilize cash flows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising raw material, energy and labor costs in 2025—after Mexico's 2024 inflation averaged 5.8% and global pharmaceutical input prices rose ~6% YoY—are squeezing Genomma Lab's manufacturing margins; energy costs for regional plants climbed ~12% in 2024. Persistent inflation is eroding consumer purchasing power, shifting purchases toward generics and smaller SKUs, while Genomma's ability to raise prices without losing share will be a key resilience metric.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer disposable income levels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDemand for Genomma Lab’s premium personal care brands is tied to middle-class disposable income in markets like Mexico and Brazil, where real wages fell ~1.5% in 2023 and Brazil’s middle class purchasing power grew just 0.8% in 2024, pressuring premium sales.\u003c\/p\u003e\n\u003cp\u003eEconomic downturns or stagnant wage growth shift consumers to essentials, hurting discretionary wellness categories that account for ~30% of Genomma’s portfolio revenue.\u003c\/p\u003e\n\u003cp\u003eAnalysts should monitor employment rates (Mexico unemployment 3.6% in 2024) and consumer confidence indices—Mexico’s INEGI consumer confidence was down ~4 pts in 2024—to forecast revenue shifts across product lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCentral bank rate decisions drive Genomma Lab Internacional's cost of debt, affecting funding for expansion and R\u0026amp;D; Mexico's overnight rate at 11.25% in 2024 raised borrowing costs for consumer health firms and constrained capex.\u003c\/p\u003e\n\u003cp\u003eHigh-rate conditions reduce feasibility of large acquisitions or new plants; a reported 2024 net debt\/EBITDA of ~1.8x increases sensitivity to rate hikes.\u003c\/p\u003e\n\u003cp\u003eLate-2025 rate stabilization projections (markets pricing ~200–250 bps easing mid-2025) could enable debt restructuring, lowering interest expense and accelerating planned growth investments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh 2024 policy rate: 11.25% (Banxico)\u003c\/li\u003e\n\u003cli\u003eNet debt\/EBITDA ~1.8x (2024 estimate)\u003c\/li\u003e\n\u003cli\u003eMarket-implied easing 200–250 bps by mid\/late-2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain and logistics costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobal and regional economic shifts—GDP slowdowns in Latin America (2024 avg growth ~2.3%) and US freight demand volatility—raise distribution costs across Genomma Lab's broad markets, pressuring margins.\u003c\/p\u003e\n\u003cp\u003eFuel price swings (Brent averaging ~$82\/bbl in 2024) and container rate spikes (up to 40% YoY in 2023–24 for some routes) directly increase expenses for the company's vertically integrated model.\u003c\/p\u003e\n\u003cp\u003eContinual logistics optimization—warehouse consolidation, route planning, and modal shifts—remains essential to preserve competitive pricing and protect FY2024–25 COGS and gross margin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 LATAM GDP ~2.3% affects demand\u003c\/li\u003e\n\u003cli\u003eBrent ~$82\/bbl (2024) raises transport costs\u003c\/li\u003e\n\u003cli\u003eContainer rates saw regional spikes up to +40% YoY\u003c\/li\u003e\n\u003cli\u003eLogistics efficiency critical to protect COGS\/gross margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMXN volatility, high rates and rising costs squeeze margins; premium SKUs under pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFX volatility (MXN ±7.5% y\/y 2024) and $240m net debt (FY2023) raise interest\/import costs; 2024 Banxico rate 11.25% and net debt\/EBITDA ~1.8x constrain capex; LATAM GDP ~2.3% (2024) and Brent ~$82\/bbl lift logistics\/COGS; inflation ~5.8% (MX 2024) shifts consumers to value SKUs, pressuring premium categories (~30% revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBanxico rate\u003c\/td\u003e\n\u003ctd\u003e11.25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMXN vol\u003c\/td\u003e\n\u003ctd\u003e±7.5% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$240m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~1.8x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLATAM GDP\u003c\/td\u003e\n\u003ctd\u003e~2.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrent\u003c\/td\u003e\n\u003ctd\u003e$82\/bbl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eGenomma Lab Internacional PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Genomma Lab Internacional PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751484404089,"sku":"genommalab-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/genommalab-pestle-analysis.png?v=1772232002","url":"https:\/\/growthsharematrix.com\/products\/genommalab-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}